Original news and analysis on international IP policy
MUNICH -- The agreement of the heads of states of the United States, Canada, Japan, United Kingdom, France, Italy and Germany to reduce global warning to less than two degrees made the biggest headlines of the G7 Summit on Elmau Castle, Germany, in the Bavarian Alps. Also agreed were commitments on trade and on public health, including research and development for neglected diseases.
MUNICH -- Just days before leaders of the Group of 7 (G7) industrialised countries gather in the well-guarded Bavarian Castle Elmau, a broad coalition of organisations invited free trade critics to an International Summit for Alternatives in Munich. Speaking there, Jean Ziegler, well-known former UN rapporteur for the right to food, shrugged off the possible effects of the G7 Summit.
Patent activity is currently at an all-time high, with statistics showing large growth across industry sectors in the volume of patents being filed. However, the production of scientific literature is declining, according to a new report from Thomson Reuters.
European Commission negotiators should back away from a controversial provision in the Transatlantic Trade and Investment Partnership (TTIP) deal that would allow companies to sue governments in arbitration courts over claimed unequal treatment, the European Parliament International Trade Committee (INTA) said on 28 May. MEPs called instead for publicly appointed, independent judges, public hearings and an appellate mechanism that respects the jurisdiction of EU and national courts, the committee said.
The high prices of medicine, which affects access to affordable medicine, was a theme of the annual World Health Assembly over the past week. In one side event, a panel discussed compulsory licensing as a vehicle to be used in combatting the high prices of medicine, not only in developing countries, but in Europe.
The European Council of member states yesterday adopted a decision asking the European Commission to draft legislation on Europe’s ratification of the Marrakesh Treaty on increasing access to publications for blind and visually impaired readers.
Pharmaceutical company Gilead Sciences has been noted first for developing a treatment for hepatitis C, which afflicts tens of millions around the world, and then for pricing it at jaw-dropping prices ($1000 per pill) in the United States and elsewhere. Now a group of health advocates has challenged Gilead's patent applications in five emerging economies.
WARSAW -- More than twenty years after Poland’s parliament passed the Authors’ and Related Rights law of 1994, the Polish government is drafting three bills to modify the country’s intellectual property legislation. The first of the drafts prepared by the Polish Ministry of Culture and National heritage was submitted to the Parliament in March, and is currently being deliberated, while the ministry is finishing work on the remaining two drafts.
The German Federation of Blind and Partially Sighted today sounded the alarm over another dispute about the "Marrakesh Treaty to Facilitate Access to Published Works for Persons Who Are Blind, Visually Impaired or Otherwise Print Disabled". The German and the Italian governments are blocking a compromise on the path for ratification in the European Union, the Blind Federation said in a press release. The EU Council of Ministers is expected to take a decision on the ratification next week
Just days before the start of the Diplomatic Conference for the Adoption of a new Act of the Lisbon Agreement for the Protection of Appellations of Origins and their International Registration, several committees of the European Parliament considered a recommendation to extend existing geographical indication protection in the European Union to non-agricultural products.